We indicated that elevated BRD9 expression was linked to an adverse prognosis, with regards to OS, for adrenocortical carcinoma (ACC), LIHC, mesothelioma (MESO) and sarcoma (SARC) cohorts (Figure 3A). Here, BRD9 is linked to adrenal cortex carcinoma.